GlassScriptPhysician profile
Ami K Patel
NPI 1902100746
$1,814.66
in general payments reported to CMS, 2019-2025
23 companies · $13.72 in 2025
The $13.72 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $139 · 2021: $354 · 2022: $60.32 · 2023: $638 · 2024: $609 · 2025: $13.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.06 |
| Education | $249.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $506.62 | 2021-2024 | Cresemba, Lexiscan |
| Abbvie INC. | $365.02 | 2021-2025 | |
| Novo Nordisk INC | $210.98 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $94.49 | 2021-2023 | Recarbrio, Zerbaxa, Dificid |
| Allergan, INC. | $91.43 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.67 | 2020-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $76.23 | 2024 | |
| Mannkind Corporation | $57.63 | 2023 | Afrezza |
| Viiv Healthcare Company | $42.31 | 2024 | Cabenuva, Dovato |
| Amgen INC. | $34.47 | 2023-2024 | Evenity, Prolia |
| Kyowa Kirin, INC. | $32.02 | 2023 | Crysvita |
| Ferring Pharmaceuticals INC. | $29.39 | 2023 | Rebyota |
| Aimmune Therapeutics, INC. | $27.44 | 2024 | |
| Radius Health, INC. | $27.24 | 2024 | Tymlos |
| Abbott Laboratories | $24.70 | 2024 | Freestyle Libre 2 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $17.81 | 2024 | Teriparatide |
| Gilead Sciences, INC. | $15.47 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.98 | 2023 | Strensiq |
| Medtronic, INC. | $14.70 | 2023 | Minimed 780g |
| Tandem Diabetes Care, INC. | $14.20 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $13.07 | 2024 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $12.65 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $12.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.